India’s Dr. Reddy’s Laboratories, which has been whiplashed repeatedly by FDA actions against its plants, saw its sales in the U.S. fall markedly in the last…

​​​​​​​Rocked by a corruption scandal in Korea, Novartis is working to strengthen and simplify its global ethics and compliance approach.

Generic drug companies, as well as their branded counterparts, worked through a tumultuous year in 2016.

Wockhardt reported a widened Q4 loss, Takeda penned a T-cell platform deal, and the FDA approved Mitsubishi’s ALS drug Radicava.

Takeda’s plan to launch a Hib vaccine in Japan has ended in smoke as GlaxoSmithKline has terminated production of Vaxem Hib.

The FDA has warned Vikshara Trading & Investments for its repeated efforts to keep inspectors from getting a look into its filthy plant.

The FDA has cited an Aurobindo sterile manufacturing plant in India for not doing everything it can to prevent contamination, according to a new report.

India’s Wockhardt saw its losses widen last year as its burgeoning regulatory issues with the FDA continue to chainsaw away at its finances.

Pharma Asia